| [1] | 
																						 
											  Yu J, Sheng Z, Wu S, et al. Tumor DNA from tumor in situ fluid reveals mutation landscape of minimal residual disease after glioma surgery and risk of early recurrence[J]. Front Oncol, 2021, 11: 742037. DOI: 10.3389/fonc.2021.742037. 
											 											 | 
										
																													
																						| [2] | 
																						 
											  李锋, 王国辉, 常晓静, 等. 高级别脑胶质瘤术后同步加量与序贯加量调强放疗疗效比较[J]. 中华放射肿瘤学杂志, 2022, 31(6): 513-518. DOI: 10.3760/cma.j.cn113030-20210823-00317.
											 											 | 
										
																													
																						| [3] | 
																						 
											  Piotrowski AF, Jackson S. Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: moving forward by looking back[J]. Neuro Oncol, 2022, 24(8): 1387-1388. DOI: 10.1093/neuonc/noac081. 
											 											 | 
										
																													
																						| [4] | 
																						 
											  Luo C, Luo Q, Xu Y, et al. Analysis of clinical characteristics and risk factors of postoperative recurrence and malignant transformation of low-grade glioma[J]. J Oncol, 2022, 2022: 4948943. DOI: 10.1155/2022/4948943.
											 											 | 
										
																													
																						| [5] | 
																						 
											  《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J]. 中华医学杂志, 2016, 96(7): 485-509. DOI: 10.3760/cma.j.issn.0376-2491.2016.07.003.
											 											 | 
										
																													
																						| [6] | 
																						 
											  Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: cardiooncology state-of-the-art review[J]. JACC: Cardiooncology, 2021, 3(2): 173-190. DOI: 10.1016/j.jaccao.2021.03.001. 
											 											 | 
										
																													
																						| [7] | 
																						 
											  林艺, 王策, 康勋, 等. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23. DOI: 10.19401/j.cnki.1007-3639.2022.01.002. 
											 											 | 
										
																													
																						| [8] | 
																						 
											  Zheng H, Yan TN, Han YS, et al. Nomograms for prognostic risk assessment in glioblastoma multiforme: applications and limitations[J]. Clin Genet, 2022, 102(5): 359-368. DOI: 10.1111/cge.14200. 
											 											 | 
										
																													
																						| [9] | 
																						 
											  Huang RH, Wang TW, Liao ZJ, et al. A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma[J]. Ann Palliat Med, 2021, 10(5): 5391-5399. DOI: 10.21037/apm-21-823. 
											 											 | 
										
																													
																						| [10] | 
																						 
											  Teng CB, Zhu YW, Li YS, et al. Recurrence- and malignant progression-associated biomarkers in low-grade gliomas and their roles in immunotherapy[J]. Front Immunol, 2022, 13: 899710. DOI: 10.3389/fimmu.2022.899710. 
											 											 | 
										
																													
																						| [11] | 
																						 
											  孟凡萱, 崔久嵬. 血小板:肿瘤诊断与治疗的新兴靶点[J]. 中国肿瘤生物治疗杂志, 2023, 30(1): 10-19. DOI: 10.3872/j.issn.1007-385x.2023.01.002.
											 											 | 
										
																													
																						| [12] | 
																						 
											  Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus[J]. Cancer Metastasis Rev, 2017, 36(2): 249-262. DOI: 10.1007/s10555-017-9673-1. 
											 											 | 
										
																													
																						| [13] | 
																						 
											  Xu WP, Xu HH, Fang MM, et al. MKL1 links epigenetic acti-vation of MMP2 to ovarian cancer cell migration and invasion[J]. Biochem Biophys Res Commun, 2017, 487(3): 500-508. DOI: 10.1016/j.bbrc.2017.04.006. 
											 											 | 
										
																													
																						| [14] | 
																						 
											  Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer[J]. Cancer Metastasis Rev, 2017, 36(2): 263-272. DOI: 10.1007/s10555-017-9674-0. 
											 											 | 
										
																													
																						| [15] | 
																						 
											  Dincel O, Bayraktar C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma[J]. Bratisl Lek Listy, 2017, 118(3): 153-155. DOI: 10.4149/BLL_2017_030. 
											 												 
																																					pmid: 28319410
																							 											 | 
										
																													
																						| [16] | 
																						 
											  Wang X, Cui MM, Xu YY, et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer[J]. Oncotarget, 2017, 8(40): 68115-68122. DOI: 10.18632/oncotarget.19242. 
											 												 
																																					pmid: 28978101
																							 											 |